Recursion Pharmaceuticals Stock Total Asset
| RXRX Stock | USD 8.58 0.04 0.46% |
Recursion Pharmaceuticals fundamentals help investors to digest information that contributes to Recursion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Recursion Stock. The fundamental analysis module provides a way to measure Recursion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Recursion Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 653.7 M | 520.4 M | |
| Intangibles To Total Assets | 0.14 | 0.14 |
Recursion | Total Asset |
Recursion Pharmaceuticals Company Total Asset Analysis
Recursion Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Recursion Pharmaceuticals Total Asset | 653.7 M |
Most of Recursion Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Recursion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Recursion Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Recursion Pharmaceuticals is extremely important. It helps to project a fair market value of Recursion Stock properly, considering its historical fundamentals such as Total Asset. Since Recursion Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Recursion Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Recursion Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Recursion Total Asset Historical Pattern
Today, most investors in Recursion Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Recursion Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Recursion Pharmaceuticals total asset as a starting point in their analysis.
Recursion Pharmaceuticals Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Recursion Total Assets
Total Assets |
|
Based on the latest financial disclosure, Recursion Pharmaceuticals has a Total Asset of 653.7 M. This is 91.31% lower than that of the Biotechnology sector and 66.92% lower than that of the Health Care industry. The total asset for all United States stocks is 97.78% higher than that of the company.
Recursion Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Recursion Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Recursion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Recursion Pharmaceuticals by comparing valuation metrics of similar companies.Recursion Pharmaceuticals is currently under evaluation in total asset category among its peers.
Recursion Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Recursion Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Recursion Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Recursion Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Recursion Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Recursion Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Recursion Pharmaceuticals' value.| Shares | Data Collective Iv Gp, Llc | 2024-03-31 | 5.9 M | Dcvc Opportunity Fund Ii Gp, Llc | 2024-03-31 | 4 M | Norges Bank | 2023-12-31 | 3.5 M | Geode Capital Management, Llc | 2024-03-31 | 3.5 M | Exor Investments (uk) Llp | 2024-03-31 | 2.2 M | Dimensional Fund Advisors, Inc. | 2024-03-31 | 2.1 M | Morgan Stanley - Brokerage Accounts | 2024-03-31 | 2 M | Credit Suisse First Boston (csfb) | 2024-03-31 | 1.9 M | Junked Platinum Investment Management Ltd | 2024-03-31 | 1.8 M | Ark Investment Management Llc | 2024-03-31 | 24.6 M | Baillie Gifford & Co Limited. | 2024-03-31 | 24.1 M |
Recursion Fundamentals
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (6.98) % | ||||
| Current Valuation | 1.8 B | ||||
| Shares Outstanding | 230.27 M | ||||
| Shares Owned By Insiders | 5.20 % | ||||
| Shares Owned By Institutions | 97.20 % | ||||
| Number Of Shares Shorted | 42.37 M | ||||
| Price To Book | 4.26 X | ||||
| Price To Sales | 44.27 X | ||||
| Revenue | 44.58 M | ||||
| Gross Profit | (164.13 M) | ||||
| EBITDA | (317.6 M) | ||||
| Net Income | (328.07 M) | ||||
| Cash And Equivalents | 515.44 M | ||||
| Cash Per Share | 2.98 X | ||||
| Total Debt | 50.67 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 1.69 X | ||||
| Cash Flow From Operations | (287.78 M) | ||||
| Short Ratio | 8.27 X | ||||
| Earnings Per Share | (1.63) X | ||||
| Price To Earnings To Growth | (0.60) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 500 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 2.01 B | ||||
| Total Asset | 653.7 M | ||||
| Retained Earnings | (967.62 M) | ||||
| Working Capital | 344.97 M | ||||
| Net Asset | 653.7 M |
About Recursion Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Recursion Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Recursion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Recursion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.